diabet
endotheli
cell
angiotensinogen
angiotensin
angiotensin
ii
renin
ace
g
b
figur
podocyt
renin
angiotensin
system
mechan
increas
express
decreas
local
angiotensin
ii
product
angiotensinconvert
enzym
angiotensin
angiotensin
angiotensin
ii
type
receptor
gbm
glomerular
basement
membran
th
e
renin
angiotensin
system
ra
phylogenet
ancient
import
mainten
physiolog
homeostasi
reflect
ten
thousand
public
subject
howev
although
renin
fi
rst
describ
angiotensin
investig
continu
discov
new
facet
ra
th
e
role
monocarboxyl
peptidas
angiotensinconvert
enzym
physiolog
pathophysiolog
attract
increas
interest
ace
convert
decapeptid
angiotensin
angiotensin
ii
remov
two
distal
amino
acid
act
angiotensin
angiotensin
ii
situat
remov
distal
amino
acid
lead
product
angiotensin
angiotensin
respect
metabol
ace
give
although
share
approxi
mate
homolog
classic
ace
product
separ
gene
separ
regulatori
control
importantli
ace
inhibitor
clinic
practic
inhibit
gener
studi
indic
respons
counteract
gener
acemedi
product
angiotensin
ii
promot
vasodil
natriuresi
cytoprotect
mice
global
delet
increas
respons
ra
activ
matern
defi
cienci
lead
fetal
growth
restrict
possibl
secondari
increas
placent
concentr
angiotensin
ii
also
implic
regul
oxid
stress
paraventricular
nucleu
rostral
ventrolater
medulla
may
modul
sympathet
tone
blood
pressur
although
manner
relat
role
regul
ra
serv
receptor
lung
sever
acut
respiratori
syndrom
coronaviru
cient
mice
develop
lung
injuri
upon
exposur
viru
th
ere
remain
uncertainti
exactli
eff
ect
mediat
one
hand
convers
angiotensin
angiotensin
ii
modul
amount
angio
tensin
ii
avail
activ
angio
tensin
ii
type
receptor
hand
ligand
ma
receptor
activ
report
mediat
vaso
dilat
natriuresi
reduct
blood
pressur
depend
tissu
pathophysiolog
condit
one
mechan
may
predomin
may
work
concert
event
abnorm
express
activ
implic
rang
disord
includ
hypertens
cardiovascular
diseas
diabet
nephropathi
studi
patient
diabet
nephropathi
shown
increas
ace
ratio
glomerulu
tubulo
interstitium
due
larg
decreas
express
previou
studi
diabet
mice
found
either
global
delet
pharmacolog
inhibit
exacerb
develop
diabet
nephropathi
although
studi
report
alter
blood
pressur
inhibit
activ
express
amelior
diabet
nephropathi
system
administr
recombin
increas
system
adenovir
express
associ
decreas
blood
pressur
make
difficult
discern
whether
benefici
effect
local
respons
kidney
secondari
system
eff
ect
blood
pressur
glomerulu
podocyt
express
mani
compon
ra
includ
pro
renin
receptor
angiotensinogen
ace
angiotensin
ii
type
receptor
podocyt
also
express
although
glomerular
express
ma
receptor
remain
uncertain
previou
studi
ma
detect
glomeruli
proxim
tubul
juxtamedullari
region
although
global
delet
ma
induc
hyperfi
ltration
albuminuria
figur
order
test
directli
role
local
glomerular
diabet
nephropathi
nadarajah
et
al
issu
develop
mous
model
select
podocyt
overexpress
coupl
human
transcript
nephrin
promot
th
e
mice
fvb
n
background
rel
sensit
develop
diabet
nephro
pathi
mice
render
diabet
streptozotocin
administr
select
overexpress
podocyt
delay
onset
sever
function
structur
glomerular
chang
specifi
calli
delay
onset
signific
albuminuria
delay
develop
signifi
cant
mesangi
expans
partial
preserv
podocyt
number
delay
increas
glomerular
express
transform
growth
factor
tgf
preserv
express
podocyt
marker
nephrin
synaptopodin
notabl
chang
accompani
detect
diff
erenc
blood
pressur
wildtyp
transgen
diabet
mice
suggest
observ
benefi
cial
eff
ect
due
direct
local
eff
ect
glomerulu
wellperform
studi
result
rais
number
interest
question
first
foremost
cours
exact
mechan
site
action
eff
ect
due
rel
inhibit
local
podocyt
angiotensin
ii
product
angiotensin
ii
type
receptor
activ
one
might
expect
administr
ace
inhibitor
angiotensin
receptor
blocker
might
addit
benefi
seen
transgen
mice
convers
increas
underli
observ
benefi
cial
eff
ect
podocyt
overexpress
site
action
evid
date
podocyt
express
ma
regard
group
previous
describ
cultur
mesangi
cell
express
ma
respond
question
includ
site
product
role
alter
tgfin
eff
ect
especi
sinc
aforement
studi
mesangi
cell
indic
actual
stimul
tgfproduct
rather
inhibit
previou
studi
group
nephrectomi
mous
model
inhibit
worsen
proteinuria
administr
eff
ect
actual
increas
mesangi
expans
summari
studi
nadarajah
et
al
clearli
show
podocyt
overexpress
delay
amelior
develop
glomerulopathi
type
model
diabet
indic
addit
system
eff
ect
slow
diabet
nephropathi
direct
eff
ect
glomerulu
th
erefor
modul
pathway
repres
potenti
excit
target
therapeut
intervent
studi
unravel
mechan
underli
protect
requir
order
determin
whether
increas
activ
activ
signal
pathway
success
mode
intervent
figur
author
declar
compet
interest
